Omeros (OMER) News Today $9.18 -0.43 (-4.47%) Closing price 04:00 PM EasternExtended Trading$9.46 +0.29 (+3.10%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Omeros announces results for narsoplimab expanded access programFebruary 21 at 10:34 PM | finance.yahoo.comOmeros (NASDAQ:OMER) Given Buy Rating at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research report on Thursday.February 21 at 5:47 PM | marketbeat.comOmeros (NASDAQ:OMER) Trading Up 6.9% - Here's What HappenedOmeros (NASDAQ:OMER) Trading 6.9% Higher - Time to Buy?February 21 at 12:32 PM | marketbeat.comOmeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMAFebruary 20 at 12:30 PM | uk.finance.yahoo.comOmeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?Omeros (NASDAQ:OMER) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?February 19 at 6:09 AM | marketbeat.comOmeros Co. (NASDAQ:OMER) Receives $22.50 Average PT from BrokeragesFebruary 14, 2025 | americanbankingnews.comOmeros Co. (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by AnalystsShares of Omeros Co. (NASDAQ:OMER - Get Free Report) have earned an average rating of "Moderate Buy" from the five analysts that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy ratFebruary 11, 2025 | marketbeat.comInstitutions own 43% of Omeros Corporation (NASDAQ:OMER) shares but retail investors control 53% of the companyFebruary 10, 2025 | finance.yahoo.comOmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access ProgramFebruary 10, 2025 | businesswire.com40,000 Shares in Omeros Co. (NASDAQ:OMER) Purchased by Stordahl Capital Management Inc.Stordahl Capital Management Inc. acquired a new stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 40,000 shares of the biopharmaJanuary 30, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Trading Up 5.3% - Here's What HappenedOmeros (NASDAQ:OMER) Trading Up 5.3% - What's Next?January 27, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Shares Down 4.4% - What's Next?Omeros (NASDAQ:OMER) Stock Price Down 4.4% - What's Next?January 24, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Shares Gap Down - Time to Sell?Omeros (NASDAQ:OMER) Shares Gap Down - Here's What HappenedJanuary 22, 2025 | marketbeat.comBrokers Offer Predictions for Omeros FY2025 EarningsOmeros Co. (NASDAQ:OMER - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Omeros in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer anticipates that the biopharmaceutical company will post earnings of ($1.73) peJanuary 22, 2025 | marketbeat.comBarclays PLC Has $376,000 Holdings in Omeros Co. (NASDAQ:OMER)Barclays PLC grew its stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 121.3% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 94,640 shares of the biopharmaceutical company's stock after purchasing an additional 51,873 shares durJanuary 19, 2025 | marketbeat.comOmeros' (OMER) "Hold" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Omeros in a research report on Friday.January 17, 2025 | marketbeat.comOmeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Omeros Co. (NASDAQ:OMER - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, two have given a buy rating and one haJanuary 17, 2025 | marketbeat.comNarsoplimab shows promise in reducing mortality for TA-TMA patientsJanuary 16, 2025 | msn.comOmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary EndpointJanuary 16, 2025 | finance.yahoo.comOmeros (NASDAQ:OMER) Shares Up 5.5% - Here's What HappenedOmeros (NASDAQ:OMER) Stock Price Up 5.5% - Time to Buy?January 16, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $36.00 price target on shares of Omeros in a report on Thursday.January 16, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Shares Down 3.1% - Here's WhyOmeros (NASDAQ:OMER) Stock Price Down 3.1% - Should You Sell?January 6, 2025 | marketbeat.comOmeros Co. (NASDAQ:OMER) Shares Acquired by Barclays PLCBarclays PLC increased its stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 121.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,640 shares of the biopharmaceutical company's stock after puJanuary 4, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Trading Up 10.3% - Here's What HappenedOmeros (NASDAQ:OMER) Stock Price Up 10.3% - What's Next?January 3, 2025 | marketbeat.comOmeros (NASDAQ:OMER) Shares Gap Up - Should You Buy?Omeros (NASDAQ:OMER) Shares Gap Up - Should You Buy?December 31, 2024 | marketbeat.comOmeros (NASDAQ:OMER) Shares Gap Down - What's Next?Omeros (NASDAQ:OMER) Shares Gap Down - Here's WhyDecember 30, 2024 | marketbeat.comOmeros (NASDAQ:OMER) Trading Up 3.6% - Should You Buy?Omeros (NASDAQ:OMER) Shares Up 3.6% - Still a Buy?December 27, 2024 | marketbeat.comWhen Can We Expect A Profit From Omeros Corporation (NASDAQ:OMER)?December 27, 2024 | finance.yahoo.comOmeros initiated with a Buy at D. Boral CapitalDecember 24, 2024 | markets.businessinsider.comOmeros (NASDAQ:OMER) Shares Gap Down - Should You Sell?Omeros (NASDAQ:OMER) Shares Gap Down - Here's What HappenedDecember 24, 2024 | marketbeat.comD. Boral Capital Initiates Coverage of Omeros (OMER) with Buy RecommendationDecember 24, 2024 | msn.comThis Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For MondayDecember 23, 2024 | benzinga.comOmeros (NASDAQ:OMER) Now Covered by D. Boral CapitalD. Boral Capital initiated coverage on shares of Omeros in a research note on Monday. They issued a "buy" rating and a $36.00 price objective for the company.December 23, 2024 | marketbeat.comOmeros reports survival benefit with narsoplimab in TA-TMADecember 21, 2024 | uk.investing.comWellington Management Group LLP Invests $305,000 in Omeros Co. (NASDAQ:OMER)Wellington Management Group LLP purchased a new position in shares of Omeros Co. (NASDAQ:OMER - Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 76,945 shares of the biopharmaceutical company's stock, vaDecember 21, 2024 | marketbeat.comOmeros' (OMER) Hold Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Thursday.December 20, 2024 | marketbeat.comOmeros Reports Narsoplimab TA-TMA Trial Success; Stock SurgesDecember 20, 2024 | finance.yahoo.comOmeros Stock Gains 52% On Successful Trial ResultsDecember 20, 2024 | marketwatch.comOmeros jumps as lead drug succeeds in pivotal trial for blood transplant patientsDecember 20, 2024 | msn.comOmeros (NASDAQ:OMER) Reaches New 12-Month High - Still a Buy?Omeros (NASDAQ:OMER) Hits New 12-Month High - What's Next?December 20, 2024 | marketbeat.comOmeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock SurgesDecember 19, 2024 | benzinga.comOmeros stock surges on positive survival data for narsoplimabDecember 19, 2024 | investing.comOmeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMADecember 19, 2024 | businesswire.comOmeros announces narsoplimab trial meets primary endpointDecember 19, 2024 | tipranks.comOmeros Co. (NASDAQ:OMER) Short Interest UpdateOmeros Co. (NASDAQ:OMER - Get Free Report) was the recipient of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 8,920,000 shares, a decline of 16.9% from the November 15th total of 10,730,000 shares. Approximately 16.1% of the company's shares are short sold. Based on an average trading volume of 701,200 shares, the short-interest ratio is presently 12.7 days.December 14, 2024 | marketbeat.comOmeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key UpdatesDecember 12, 2024 | seekingalpha.comOmeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial ChallengesDecember 10, 2024 | insidermonkey.comOmeros (NASDAQ:OMER) Stock Price Up 7.8% - Still a Buy?Omeros (NASDAQ:OMER) Stock Price Up 7.8% - Here's WhyDecember 6, 2024 | marketbeat.comLightning Round: Take a pass on AstraZeneca, says Jim CramerDecember 2, 2024 | msn.comOmeros Corp (OMER) Stock Surges Amid Biotech Sector ActivityDecember 2, 2024 | gurufocus.com Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address OMER Media Mentions By Week OMER Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OMER News Sentiment▼0.290.60▲Average Medical News Sentiment OMER News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OMER Articles This Week▼52▲OMER Articles Average Week Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCRX News NKTR News ASMB News CPIX News LLY News JNJ News ABBV News MRK News PFE News BMY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OMER) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OMER Stock Alerts